Vistagen Therapeutics, Inc. (VTGN)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Mar 31
In fiscal 2026, Vistagen Therapeutics, Inc. reported revenue of $1.27M, up 161.1% from the prior year. The company ran a net loss, with a net margin of -5491.3%. It held $48.56M in total assets against $13.04M in total liabilities.
Key ratios (FY2026)
-5683.7%
Operating margin
-5491.3%
Net margin
-196.2%
Return on equity
+161.1%
Revenue growth (YoY)
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.27M | $486.0K | $1.06M | — | $1.11M | $1.09M | — | — | — | — |
| Operating Income | -$72.13M | -$55.97M | -$33.02M | -$59.27M | -$47.78M | -$17.93M | -$20.80M | -$24.56M | -$14.20M | -$10.25M |
| Net Income | -$69.69M | -$51.42M | -$29.36M | -$59.25M | -$47.76M | -$17.93M | -$20.77M | -$24.59M | -$14.35M | -$10.26M |
| EPS (Diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | — | — | — | — | — | — |
| Total Assets | $48.56M | $84.34M | $123.65M | $21.09M | $74.64M | $108.28M | $5.77M | $14.01M | $11.28M | $3.71M |
| Total Liabilities | $13.04M | $13.95M | $9.37M | $9.01M | $9.93M | $16.30M | $11.50M | $6.94M | $4.36M | $3.10M |
| Shareholders' Equity | $35.52M | $70.39M | $114.29M | $12.08M | $64.72M | $91.98M | -$5.73M | $7.08M | $6.92M | $615.8K |
| Cash & Equivalents | $30.79M | $67.13M | $119.17M | $16.64M | $68.14M | $103.11M | $1.36M | $13.10M | $10.38M | $2.92M |
| Operating Cash Flow | -$66.44M | -$42.10M | -$25.81M | -$49.72M | -$45.26M | -$12.07M | -$15.76M | -$14.53M | -$9.06M | — |
| Capital Expenditures | — | — | $0 | $528.0K | $0 | — | — | — | — | — |
| Shares Outstanding | 38.07M | 30.88M | 19.35M | 6.96M | — | — | — | — | — | — |